




PREPARATION AND EVALUATION OF NILVADIPNE LIQUISOLID COMPACTS 
Review Article 
 
MOHAMMED ASIF HUSSAIN1, MANISH GORRE1*, T. RAMA RAO2, MAIMUNA ANJUM1 
1Blue Birds College of Pharmacy, Bheemaram, Warangal, A.P, INDIA 506001, 2
 Received: 19 Feb 2014 Revised and Accepted: 27 Mar 2014 
Avanthi Institute of Pharmaceutical Sciences, Gunthapally 
(V), Hayathnagar- 501512, Ranga Reddy Dist, Andhra Pradesh, India. 
Email: kalliammanish7@gmail.com 
ABSTRACT 
The purpose of the present study is to develop a novel liquid solid technique which enhances the dissolution rate of water insoluble or poorly water 
soluble drugs of Nilvadipine, which belong to class II of BCS. Generally the liquisolid technique is based upon the admixture of drug loaded with non 
volatile solutions (or) liquid drug incorporated with required carrier and coating materials in order to obtain a dry, non adherent, free flowing and 
compressible powder. Various non volatile solvents used were Propylene glycol, Poly ethylene glycol. The solubility of drug in the non volatile 
solvents plays an important role in this formulation Avicel PH 102 and aerosil were used as carrier and coating materials. Super disintegrants were 
used to increase the dissolution rate.Evaluation tests such as Disintegration time, Friability, Hardness and in-vitro dissolution studies were 
conducted. Amongst all the formulations F14 was considered to be the best in which Propylene glycol is used and the drug release was found to be 
97% in 10 min. 
Keywords: Nilvadipine, PEG, PG, Avicel PH 102, Aerosil, Super disintegrants. 
 
INTRODUCTION  
Solubility is the major challenge in the pharmaceutical industry for 
the development of new pharmaceutical products. Poor dissolution 
characteristics of water insoluble drugs are a major challenge for 
pharmaceutical scientists. It is well known that the active ingredient 
in a solid dosage form must undergo dissolution before it is available 
for absorption from the gastro intestinal tract[1].Several studies 
with poorly soluble drugs have demonstrated that particle size 
reduction to the sub micron range can lead to an increase in 
dissolution rate and higher bio availability. Poorly water soluble 
drugs belong to BCS class II and IV[2]group of compounds.  
There are several techniques for enhancing solubility rate of poorly 
water soluble drugs: 
Some techniques are: 
1) Solid Dispersion[3] 
2) Particle size reduction by micronization[4] 
3) Hot melt method (Fusion method) 
4) Solvent Evaporation[5] 
5) Complexation[6] 
6) Eutectic Mixtures[7] 
7) Nano systems[8] 
8) High pressure homogenization 
9) Cryogenic technique 
10) Super critical fluid[9] 
11) Ultra rapid freezing[10] 
These are some of the techniques which are generally used to reduce 
the particle size and increase the solubility. Nilvadipine acts a 
calcium channel blocker &anti hypertensive agent. Nilvadipine 
inhibits the influx of extracellular calcium through myocardial and 
vascular membrane pores by physically plugging the channel. The 
decrease in intracellular calcium inhibits the contractile processes of 
smooth muscle cells, causing dilation of the coronary and systemic 
arteries, increased oxygen delivery to the myocardial tissue, 
decreased total peripheral resistance, decreased systemic blood 
pressure, and decreased after load.The rate of oral absorption is 
often controlled by the dissolution rate in the GI tract. 
MATERIALS AND METHODS 
Nilvadipine was obtained from TCI Chemicals, Chennai, India. MCC, 
PEG and PG was obtained from SD fine chemicals Mumbai, India. 
Aerosil was obtained from Fischer Scientific pvt ltd. Super 
disintegrants like crospovidone, croscarmellose, sodium starch 
glycolate were bought from Yarrow chemicals Mumbai, India. 
Solubility studies 
In order to select the best and compatible non volatile solvent, 
solubility studies[11] were performed by dissolving the minimum 
dose of drug 4 mg in 0.1, 0.2, 0.3,.. ml of the non volatile solvents like 
PEG,PG & tween 80 and subjected for solubility. The solvent which 
utilizes the less amount of liquid to dissolve the drug is selected as 
the best solvent. In this present study PEG & PG utilized minimum 
quantities of the solvents to dissolve the drug. 
Preparation of Liqui-solid Tablets [12] 
Preparation of Liquid Medication 
From the results of solubility studies, various types of non-volatile 
solvents are chosen for dissolving the drug. AvicelpH 102 as carrier 
and Aerosil as the coating material[13] is selected for the 
preparation of liquisolid compacts. Various ratios of carrier to 
coating materials are selected. Based on solubility of Nilvadipine 
desired quantities of drug and a non-volatile solvents were 
accurately weighed in a beaker and then stirred continuously, until a 
homogenous drug solution/suspension was obtained. Selected 
amounts (W) of the resultant liquid medication were incorporated 
into calculated quantities of carrier contained in a mortar. 
Mixing 
The mixing procedure was conducted in three stages. During the 
first stage, the system was subjected to sonication for approximately 
one minute in order to evenly distribute the drug with the non-
volatile liquid. In the second stage, calculated quantities of carrier 
material was added to the liquid medicament and evenly spread as a 
uniform layer on the surfaces of the mortar and left standing for 
approximately 5min to allow the drug solution to be absorbed in 
interior of the powder particles. In the third stage, the coating 
material was added and triturated. After triturating calculated 
quantity of super-disintegrant was added and mixed together, 
producing the final liquisolid formulation for compression. 
Preparation of Nilvadipine conventional tablets 
Nilvadipine conventional tablets were produced by mixing the drug 
with microcrystalline cellulose, silica for a period of 10 min in a 
mortar. The mixture was mixed with disintegrant for 10 min. The 
mixture was compressed into tablets using a tablet press. Sufficient 
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compression load was applied in order to produce tablets with 
sufficient hardness. This formulation was denoted as directly 
compressed tablets. 
CALCULATION OF LIQUID LOADING FACTOR [14] 
Loading factor is calculated by dissolving the drug in the suitable 
non volatile solvents. Such liquid medication is incorporated to the 
carrier and coating materials and blended. Using the equation Lf = 
W/Q, the drug loading factors are determined and also used for 
calculating the amounts of carrier and coating materials in each 
formulation. Excipient ratio {R}: Defined as carrier to coating ratio 
quoted as: 
R=Q/q 
Q = Carrier material, 
q = Coating material. 
Liquid loading factor(Lf): Defined as weight of liquid medicament 
(W) to weight of carrier (Q). 
Lf = W/Q 
Q = W/Lf 
Lf = ΦCA+ΦCO.
The Ф – value of a powder represents the maximum amount of a 
given non volatile liquid that can be retained inside its bulk [w/w] 
while maintaining acceptable flowability.  
1/R 
Lf= Ψ + ψ. 1/R 
R is the ratio between the quantities of carrier (Q) and coating 
materials (q) present in the formulation. 
The ѱ – number of a powder is defined as the maximum amount of 
liquid the powder can retain inside its bulk [w/w] while maintaining 
acceptable compact-ability resulting in compacts of sufficient 
hardness with no liquid leaking out during compression. 
Pre Compression Studies 
Characterization of powder mixture 
The quality of tablet, once formulated by rule is generally dictated by 
the quality of physicochemical properties of blends. There are many 
formulations and process variables involved in mixing and all these 
can affect the characteristics of blends produced. 
Angle of Repose [15] 
The frictional force of a loose powder can be measured by the angle 
of repose (θ). It is defined as, the maximum angle possible between 
the surface of the pile of the powder and the horizontal plane. If 
more powder is added to the pile, it slides down the sides of the pile 
until the mutual friction of the particles produces a surface angle θ, 
is in equilibrium with the gravitational force. The fixed funnel 
method was employed to measure the angle of repose. A funnel was 
secured with its tip at a given height (h), above a graph paper is 
placed on a flat horizontal surface. The blend was carefully pored 
through the funnel until the apex of the conical pile just touches the 
tip of the funnel. The radius (r) of the base of the conical pile was 
measured. 
 
Table 1: Examples of liqui-solid formulation parameters of various powder excipients with commonly used liquid vehicles. 








Avicel pH 102 0.16 0.005 0.224 0.242 
Avicel pH 200 0.26 0.02 0.209 0.232 
Cab o sil 
With Avicel pH102 
3.31 3.26 0.560 0.653 
Cab o sil with Avicel pH 200 2.57 2.44 0.712 0.717 
 
























F1 1.635 2 229 - 140.06 70.03 - - - 4 6.71 445.7 
F2 1.635 2 229 - 140.06 70.03 8.78 - - 4 6.71 454.5 
F3 1.635 2 229 - 140.06 70.03 - 8.78 - 4 6.71 454.5 
F4 1.635 2 229 - 140.06 70.03 - - 8.78 4 6.71 454.5 
F5 1.088 3 229 - 210.47 70.15 - - - 4 7.7 515.9 
F6 1.088 3 229 - 210.47 70.15 10.1 - - 4 7.7 526 
F7 1.088 3 229 - 210.47 70.15 - 10.1 - 4 7.7 526 
F8 1.088 3 229 - 210.47 70.15 - - 10.1 4 7.7 526 
F9 1.815 2 - 107.5 59.22 29.61 - - - 4 3.01 200.07 
F10 1.815 2 - 107.5 59.22 29.61 3.93 - - 4 3.01 204 
F11 1.815 2 - 107.5 59.22 29.61 - 3.93 - 4 3.01 204 
F12 1.815 2 - 107.5 59.22 29.61 - - 3.93 4 3.01 204 
F13 1.263 3 - 107.5 85.11 28.37 - - - 4 3.37 223.5 
F14 1.263 3 - 107.5 85.11 28.37 4.41 - - 4 3.37 228 
F15 1.263 3 - 107.5 85.11 28.37 - 4.41 - 4 3.37 228 
F16 1.263 3 - 107.5 85.11 28.37 - - 4.41 4 3.37 228 
 
The angle of repose (θ) was calculated using the following formula: 
Tan θ = h/r  
Where; θ = Angle of repose  
h = Height of the cone in cms 
r = Radius of the cone base in cms 
Bulk Density [15] 
Density is defined as weight per unit volume. Bulk density (Db), is 
defined as the mass of the powder divided by the bulk volume and is 
expressed as gm/cm3
The bulk density of a powder primarily depends on particle size 
distribution, particle shape and the tendency of particles to adhere 
together.  
.  
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Bulk density is very important in the size of containers needed for 
handling, shipping, and storage of raw material and blend. It is also 
important in size blending equipment.  
The loose bulk density and tapped density were determined by 
using bulk density apparatus. Apparent bulk density was 
determined by pouring the blend into a graduated cylinder. The bulk 
volume (Vb) and weight of the powder (M) was determined. The 
bulk density was calculated using the formula. 
Db=M/Vb 
Where, M is the mass of powder, Vbis bulk volume of powder  
Tapped Density [16] 
The measuring cylinder containingknown mass of blend was tapped 
for a fixed time. The minimum volume (Vt) occupied in the cylinder 
and the weight (M) of the blend was measured. The tapped density 
was calculated using the formula. 
Dt= M/Vt 
Where, M is the mass of powder, Vt
Carr’s Index (%) [17] 
is the tapped volume of powder  
The Compressibility Index (Carr’s Index) is a measure of the 
propensity of a powder to be compressed. It is determined from the 
bulk and tapped densities. In theory, the less compressible a 
material the more flowable it is. As such, it measures the relative 
importance of interparticulate interactions. In a free-flowing 
powder, such interactions are generally less significant and the bulk 
and tapped densities will be closer in value. 
For poor flowing materials, there are frequently greater interparticle 
interactions, and a greater difference between the bulk and tapped 
densities will be observed. These differences are reflected in the 
Compressibility Index which is calculated using the following 
formulas:  
CI (%) = [(Tapped density – Bulk density) / Tapped density] x100 
The value below 15% indicates a powder which usually gives rise to 
good flow characteristics, where as above 25% indicates poor 
flowability, 1-10 showing excellent flow properties, 11-15 showing 
good flow properties 16-20 showing fair to passable, 21-25 showing 
passable.
 
Table 3: Compressibility index 
S. No. Compressibility index Flow 
1 5-12 Free flow 
2 12-16 Good flow 
3 18-21 Fair 
4 23-25 Poor 
5 33-38 Verypoor 
6 >40 Extremelypoor 
 
Hausner’s Ratio [17] 
Hausner’s ratio is an indirect index ease of powder flow. It is 
calculated by the following formula. 
 
Hausner’s Ratio=Tapped density (ρ t) / Bulk density (ρb
Where ρ
) 
t  is the tapped density and ρb
 
 is the bulk density.
Table 4: Hausner’ ratio 
S. No. Hausner’ ratio Flow 
 1 1-1.11 Free flowing 
 2 1.12-1.18 Good 
 3 1.19-1.25 Fair 
 4 1.26-1.34 Passable 
 5 1.35-1.60 Poor 
 
FT-IR Studies 
The Compatibility studies were performed using FT-IR 
spectrophotometer. The FTIR spectrum of pure drug and physical 
mixture of drug and different excipients were studied. Drug- 
excipient interactions play a vital role with respect to release of drug 
from the formulation amongst others.  
FT-IR techniques have been used here to study the physical and 
chemical interaction between drug and excipients used. In the 
present study, it has been observed that there is no chemical 
interaction between drug and the excipients used. It wasobserved 
that there were no changes in these main peaks in FT-IR spectra of 
mixture of drug and polymers, which show there were no physical 
interactions because of some bond formation between drug and 
excipients. The peaks obtained in the spectra's of each excipients 
correlates with the peaks of drug spectrum. This indicates that the 
drug was compatible with the formulation components. 
POST COMPRESSION PARAMETERS 
Physicochemical characterization of tablets 
The designed liquisolid tablets were studied for their 
physicochemical properties like weight variation, hardness, 
thickness, friability and drug content.  
Weight Variation [17] 
To study the weight variation, twenty tablets were taken and their 
weight was determined individually and collectively on a digital 
weighing balance. The average weight of one tablet was determined 
from the collective weight. The weight variation test would be a 
satisfactory method for determining the drug content uniformity. 
The percentage deviation was calculated using the following 
formula. 
% Deviation = (Individual weight – Average weight / Average 
weight) × 100 
Tablet hardness [18]; Hardness of tablet is defined as the force 
applied across the diameter of the tablet in the order to break the 
tablet. The resistance of the tablet to chipping, abrasion or breakage 
under condition of storage transformation and handling before 
usage depends on its hardness. For each formulation, the hardness 
of 6 tablets was determined by using Monsanto hardness tester and 
the average is calculated and presented with standard deviation. 
Tablet thickness [18]: Tablet thickness is an important 
characteristic in reproducing appearance. Six tablets were taken and 
their thickness was recorded using screw gauge. The average 
thickness is calculated and presented with standard deviation. 
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Friability [17]: It is to measure the mechanical strength of tablets. 
Roche friabilator (Electrolab, Mumbai, India) was used to determine 
the friability by following procedure. Preweighed tablets (10 tablets) 
were placed in the friabilator. The tablets were rotated at 25 rpm for 
4 minutes (100 rotations). At the end of test, the tablets were re-
weighed andloss in the weight of tablets is measured and is 
expressed in percentage as, 
% Friability = [(W1 – W2) / W1
Where, W
] × 100 
1
W
 = Initial weight of 20 tablets 
2
Determination of drug content [17] 
 = Weight of the 20 tablets after testing  
Ten tablets from each formulation were taken, crushed and mixed. From 
the mixture 100 mg of Nilvadipine equivalent of 1 tablet weight was 
extracted thoroughly with 100 ml of 1.2 pH phosphate buffer.  
The amount of drug present in each extract was determined using 
UV spectrophotometer at 264nm. This procedure was repeated 
thrice and the average was taken. 
  
Table 5: Pharmacopoeial specifications for tablet weight variation 
 Average weight of 
Tablets (mg) ( I.P ) 
 Average weight of  
Tablets (mg) ( U.S.P ) 
 Maximum percentage 
difference allowed 
 Less than 80  Less than 130  10 
 80-250  130-324  7.5 
 More than 250  More than 324  5 
 
Disintegration Test [19] 
Six tablets were taken randomly from each batch and placed in USP 
disintegration apparatus baskets. Apparatus was run for 10 minutes 
and the basket was lifted from the fluid, and observed whether all 
the tablets have disintegrated. 
Dissolution Test of NilvadipineLiquisolid Tablets [18], [19] 
The in-vitro dissolution study was conducted as per the United 
States Pharmacopoeia (USP). The rotating paddle method was used 
to study the drug release from the tablets. The dissolution medium 
consisted of 900 ml of phosphate buffer (1.2pH). The release was 
performed at 370C± 0.50
 The samples were filtered through whatman filter paper and 
analyzed for Nilvadipine after appropriate dilution by UV 
spectrophotometer at 264 nm. The % drug release was calculated 
using the calibration curve of the drug in phosphate buffer 1.2 pH
C, at a rotation of speed of 50 rpm. 5 ml 
samples were withdrawn at predetermined time intervals 
(2,4,6,….32 mins) and the volume was replaced with fresh medium. 
  
Table 6: Evaluation of Pre compression parameters 




Carr’s index (%) 
) 
Hausner’s ratio Angle of repose 
F1 0.336±0.003 0.394±0.012 14.81±0.65 1.17±0.021 29.3±1.04 
F2 0.292±0.002 0.363±0.011 19.35±0.37 1.24±0.012 30.9±0.93 
F3 0.313±0.007 0.378±0.009 17.24±0.98 1.20±0.039 27.1±0.48 
F4 0.324±0.004 0.412±0.008 21.42±0.49 1.27±0.093 32.5±1.06 
F5 0.318±0.002 0.404±0.018 21.21±1.02 1.26±0.062 32.9±1.25 
F6 0.362±0.006 0.438±0.006 17.24±0.93 1.20±0.038 30.9±0.99 
F7 0.389±0.002 0.478±0.004 18.5± 10.83 1.22±0.075 27.8±0.83 
F8 0.375±0.003 0.438±0.012 14.20±1.14 1.16±0.05 28.7±0.45 
F9 0.340±0.006 0.453±0.011 25±0.92 1.33±0.093 29.5±0.56 
F10 0.313±0.005 0.408±0.008 23±0.46 1.30±0.039 28.2±1.34 
F11 0.370±0.005 0.510±0.009 27.27±0.69 1.37±0.013 32.6±0.57 
F12 0.340±0.008 0.453±0.014 25±0.73 1.33±0.041 28.9±0.82 
F13 0.383±0.006 0.511±0.007 26.42±0.80 1.33±0.053 26.8±1.15 
F14 0.353±0.003 0.460±0.017 23.07±1.09 1.30±0.066 27.5±1.07 
F15 0.418±0.003 0.511±0.015 18.18±0.61 1.22±0.011 31.4±0.075 
F16 0.383±0.002 0.460±0.009 17.21±0.78 1.20±0.039  26.97±0.69 
 









F1 448.71±1.15 3.8±0.15 0.48 
F2 455.57±1.09 4.1±0.13 0.29 
F3 454.55±1.10  3.9±.17 0.15 
F4 454.92±1.08 4.0±0.19 0.19 
F5 526.14±1.90 4.3±0.24 0.23 
F6 519.65±1.76 4.2±0.152 0.26 
F7 527.33±1.85 3.7±0.161 0.15 
F8 528.36±1.95 4.3±0.164 0.34 
F9 204.43±1.25 3.9±0.172 0.58 
F10 203.52±1.19 4.0±0.098 0.47 
F11 206.11±1.28 3.8±0.103 0.20 
F12 205.55±1.08 4.3±0.091 0,45 
F13 226.41±1.27 3.7±0.087 0.30 
F14 230.08±2.15 3.8±0.16 0.44 
F15 232.02±1.93 3.9±0.175 0.34 
F16 229.50±2.07 4.2±0.194 0.47 
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Drug content (%) 
 
Disintegration(min) 
F1 4.14±0.032 95.8±1.174 0.94±0.045 
F2 4.07±0.012 92.1±1.147 1.60±0.025 
F3 4.01±0.041 90.3±1.126 2.10±0.283 
F4 4.09±0.025  88.5±1.331 3.25±0.356 
F5 4.56±0.036 93.9±1.296 2.45±0.312 
F6 4.43±0.028  87.5±1.103 3.10±0.296 
F7 4.48±0.032 88.3±1.112 4.15±0.217 
F8 4.49±0.035 84.5±2.095 3.26±0.237 
F9 3.03±0.009 85.6±1.961 1.55±0.103 
F10 3.27±0.015 89.0±1.984 0.85±0.039 
F11 3.23±0.012 91.9±1.543 4.13±0.236 
F12 3.14±0.017 96.1±1.178 1.29±0.074 
F13 3.65±0.016 98.2±1.098 2.50±0.307 
F14 3.76±0.023 92.5±1.103 3.19±0.274 
F15 3.69±0.022 93.7±1.109 2.36±0.283 
F16 3.78±0.034 88.3±1.431 3.35±0.257 
 
In Vitro drug release studies 
In Vitro drug release experiments were performed at 37±0.50
 
Fig. 2: Comparison of dissolution profiles of F1 to F4 
 
C in 
U.S.P II dissolution apparatus. The results showed that all the 
formulations release the drug within 2 to 32 min. All the 16 
formulations of Nilvadipine Liquid Solid Compacts are subjected to 
dissolution studies. Dissolution was carried out at 50 rpm in the 
volume of 900ml dissolution media (1.2pH Phosphate Buffer) for 32 
min. For all the F1 to F16 formulations done by wet granulation 
method by using Avicel used as carrier material and Aerosol used as 
coating material. The highly hydrophilic characteristic of Avicel 
could increase the wetting of drug and enhance its dissolution. 
In the prescribed dissolution data F1, F5, F9, F13 are the 
formulations done without using super-disintegrants in which only 
the carrier and coating materials were used and the time taken for 
the percentage drug release was more when compared to that of 
formulations done by using super-disintegrants.  
Whereas, F2, F6, F10, F14 are the formulations done by using 
crospovidone as super-disintegrants. In similar way F3, F7, F11, F15 
are done by using croscaramellose.F4, F8, F12, F16 are done by 
using sodium starch glycolate. 
By using crospovidone the time taken for the % drug release was 
very less when compared to that of croscarmellose and sodium 
starch glycolate. Out of the all three super disintegrants sodium 
starch glycolate took more time to release the maximum amount of 
drug this is because of poor surface area when compared to 
crospovidone, which has high interfacial activity. 
 
In case of Nilvadipineliquisolid compacts, out of all the formulations 
propylene glycol has shown greater drug release than the PEG. This 
might be due to the greater solubility of the drug in the respective 
solvent. Formulation F14 containing propylene glycol as solvent, 
which is hygroscopic liquid containing an asymmetrical carbon 
atom, it exists in two stereoisomers.  
Avicel and Aerosil as carrier and coating materials and crospovidone 
as super disintegrant, which is a water-insoluble synthetic cross 
linked homopolymer of N-vinyl-2-pyrrolidine which contains not 
less than 11.0% and not more than 12.8% of nitrogen, calculated on 
anhydrous basis has shown greater drug release than the remaining 
super-disintegrants.  
The F14 formulation was taken as optimized formulation and 
maximum percentage drug release of 97.14 was obtained within 10 
min. A single graph was plotted for four formulations by taking % 
drug release on y-axis and time on x- axis. 
 
 
Fig. 3: Comparison of dissolution profiles of F5 to F8 
 
 
Fig. 4: Comparison of dissolution profiles of F9 to F12 
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Table 9: in-vitro drug release of profiles of formulations F1 to F4 
Time (min) F1 F2 F3 F4 
0 0 0 0 0 
2 5.14±0.43 13.36±0.589 12.34±0.487 10.28±0.39 
4 10.28±1.25 26.73±0.703 27.76±0.521 24.68±0.47 
6 15.42±0.431 40.10±0.63 41.13±0.31 34.96±0.24 
8 19.53±1.19 56.56±1.07 54.50±0.97 46.27±0.631 
10 26.73±0.799 63.7±0.655 65.81±0.71 59.64±0.901 
12 33.93±0.891 80.21±0.713 76.10±1.15 71.89±0.616 
14 35.99±1.28 87.41±0.620 87.41±0.216 80.21±0.41 
16 44.22±0.81 98.72±1.07 92.55±0.523 86.38±0.502 
18 51.42±1.39  99.34±1.23 91.52±1.08 
20 57.59±1.13   97.69±0.86 
22 67.87±0.98    
24 76.10±0.37    
26 83.30±0.76    
28 89.47±1.06    
30 95.23±1.00    
32 99.75±1.39    
 
Table 10: In-vitro drug release of profiles of formulations F5 to F8 
Time (min) F5 F6 F7 F8 
0 0 0 0 0 
2 7.19±0.25 18.51±0.767 14.39±0.834 9.25±0.331 
4 12.34±0.90 34.96±1.25 29.82±0.291 19.53±0.414 
6 18.51±0.79 49.36±1.04 45.25±0.486 32.90±0.402 
8 22.62±0.503 67.87±0.96 57.59±0.312 45.25±0.517 
10 29.82±0.331 85.35±1.27 68.90±0.218 59.64±0.304 
12 34.96±0.207 97.69±0.870 78.15±0.305 71.98±1.116 
14 42.16±1.723  87.41±1.091 82.27±1.103 
16 47.30±0.491  99.03±0.798 90.50±1.03 
18 52.44±0.39   98.80±0.538 
20 57.59±0.476    
22 63.76±0.105    
24 70.96±1.52    
26 78.15±0.51    
28 85.35±0.340    
30 93.58±0.418    
32 99.96±0.513    
 
 
Fig. 5: Comparison of dissolution profiles of F13 to F16 
 
 
Fig. 6: FT-IR of Nilvadipine Pure Drug 
 
Fig. 7: FTIR For Nilvadipine With PEG 400 
 
 
Fig. 8: FT-IR of Nilvadipine best formulation 
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Fourier Transform Infrared (FTIR) spectroscopic studies 
Compatibility studies were performed using Fourier Transform 
Infrared (FTIR) spectrophotometer. The IR spectrum of pure drug 
(Nilvadipine) and physical mixture of drug and excipients were 
studied. 
The peaks obtained in the spectrum of formulation correlated with 
the peak of drug spectrum and there were no significant extra peaks. 
This indicates that the drug was compatible with the formulation 
components. The spectra of pure drug and formulation are shown in 
Fig.6 
 
Table 11: In-vitro drug release of profiles of formulations F9 to F12 
Time (min) F9 F10 F11 F12 
0 0 0 0 0 
2 6.27±0.201 15.42±0.302 14.70±0.294 10.48±1.15 
4 11.31±0.301 34.65±0.401 28.79±0.42 18.92±0.41 
6 17.59±0.59 45.04±1.256 43.19±1.02 31.42±1.93 
8 28.79±0.193 66.53±1.129 56.56±0.408 45.76±1.27 
10 35.99±0.715 83.60±0.490 70.96±0.339 58.31±0.93 
12 40.10±0.91 97.39±0.672 76.10±0.551 74.04±1.43 
14 46.27±0.22  88.44±1.16 85.35±0.84 
16 53.47±1.05  99.55±1.052 89.78±0.56 
18 60.67±1.118   99.24±1.087 
20 69.93±0.104    
22 77.13±1.099    
24 87.41±0.732    
26 99.75±0.69    
28     
30     
32     
 
Table 12: In-vitro drug release of profiles of formulations F13 to F6 
Time (min) F13 F14 F15 F16 
0 0 0 0 0 
2 6.17±0.82 19.53±0.72 16.45±0.471 18.57±0.417 
4 10.79±0.73 37.74±0.413 29.82±1.03 26.73±0.279 
6 16.45±0.65 49.15±0.639 46.27±0.732 39.07±0.624 
8 20.56±1.17 75.27±1.001 59.64±0.213 50.39±1.18 
10 25.71±0.304 97.49±0.582 81.24±1.051 65.81±1.045 
12 34.07±0.592  99.76±0.389 78.15±0.72 
14 39.07±0.421   98.52±0.831 
16 46.89±0.49    
18 59.64±0.732    
20 68.90±0.390    
22 77.13±0.473    
24 83.30±1.19    
26 91.52±0.721    
28 99.03±1.35    
30     
32     
 
CONCLUSION 
This novel technique is found to be efficient method for formulation 
of water insoluble solid drugs and liquid lipophilic drugs. Rapid 
disintegration rates are observed compared to conventional tablets 
and therefore, they show improved release rates and hence greater 
bioavailability. The use of non-volatile solvent in the formulation 
causes increased wettability of water insoluble drugs and ensures 
molecular dispersion of drug in the formulation.  
Modification of formulation by use of certain agents cause sustained 
release of drugs from the liquisolid tablets. Liquisolid Formulations 
shows better Flowability, Compressibility, improves solubility, 
dissolution and better absorption. 
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